In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vascular Biogenics (VBLT – Research Report), with a price target of $5.00. The company’s shares closed last Wednesday at $2.69.
According to TipRanks.com, DeGeeter is a top 25 analyst with an average return of 65.4% and a 67.4% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Ionis Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vascular Biogenics with a $3.92 average price target.
The company has a one-year high of $3.09 and a one-year low of $0.90. Currently, Vascular Biogenics has an average volume of 362.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.